Half-year Report

RNS Number : 1303O

Alpha Growth PLC

28 May 2020

 

Alpha Growth plc

("Alpha", or the "Company")

Interim Results

Alpha Growth plc (LSE: ALGW), the financial services specialist in the growing Senior Life Settlement ("SLS") asset class, is pleased to announce its results for the interim period ended 29 February 2020.

Gobind Sahney, Chairman of Alpha, commented:

"At the beginning of the year and through February we were quite optimistic about the Company's traction.  However, the impact of COVID19 has had an effect on the timing of various counterparties to transact with the Company and this may impact on Company's financial results in FY20 if delays should continue for an extended period of time.  However, the Company is confident that, particularly with record low interest rates, continued volatility in the equity markets and the non-correlation of SLS assets, it will be able to continue its strategies in the near terms, and also take advantage of further opportunities as and when they arise for the long term."

The full Interim results for the period ended 29 February 2020 can be downloaded here
http://www.rns-pdf.londonstockexchange.com/rns/1303O_1-2020-5-27.pdf

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

For more information, please visit www.algwplc.com or contact the following:

Alpha Growth plc	[phone]
Gobind Sahney, Executive Chairman	[e-mail]

About Alpha Growth plc

Specialist in Longevity Assets

Alpha Growth plc is a financial advisory business providing specialist consultancy, advisory, and supplementary services to institutional and qualified investors globally in the multi-billion dollar market of longevity assets. Building on its well-established network, the Alpha Growth Group has a unique position in the longevity asset services and investment business, as a listed entity with global reach. The Group's strategy is to expand its advisory and business services via acquisitions and joint ventures in the UK and the US to attain commercial scale and provide holistic solutions to alternative institutional investors who are in need of specialised skills and unique access to deploy their financial resource in longevity assets.

 

END

 

 

IR KKOBQPBKDOPB